AstraZeneca Plc said on Monday a combination of its cancer drug, Imfinzi, along with chemotherapy helped curb progression of lung cancer in a late-stage study, sending its shares up 2%. The combination, when added to the drugmaker’s tremelimumab therapy, also met the secondary goal of improving progression-free survival, the British drugmaker said. The combinations were being tested in previously untreated patients with stage four, non-small cell lung cancer. …read more
Source:: Yahoo Finance
